Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use

Pediatrics

Volumn 126, Issue 1, 2010, Pages

  Pilishvili, Tamar ^a   Zell, Elizabeth R ^a   Farley, Monica M ^b   Schaffner, William ^c   Lynfield, Ruth ^d   Nyquist, Ann Christine ^e   Vazquez, Marietta ^f   Bennett, Nancy M ^g   Reingold, Arthur ^h   Thomas, Ann ⁱ   Jackson, Delois ^a   Schuchat, Anne ^a   Whitney, Cynthia G ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MINNESOTA DEPARTMENT OF HEALTH   (United States)

^e CHILDREN S HOSPITAL COLORADO   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Office of Disease Prevention and Epidemiology   (United States)

Author keywords

Pneumococcal conjugate vaccine; Pneumococcal infections; Risk factors

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGE DISTRIBUTION; BACTEREMIA; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEEDS ASSESSMENT; PNEUMOCOCCAL INFECTIONS; REFERENCE VALUES; RISK FACTORS; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE;

EID: 77954355720     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-2150     Document Type: Article

References (35)

1. Robinson K, Baughman W, Rothrock G, et al. Epidemiology of Streptococcus pneumoniae infections in the U.S., 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285(13):1729-1735
2. Challenges in global immunization and the Global Immunization Vision and Strategy 2006-2015. Wkly Epidemiol Rec. 2006;81(19):190-195
3. Rudolph KM, Parkinson AJ, Reasonover AL, Bulkow LR, Parks DJ, Butler JC. Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998. J Infect Dis. 2000;182(2):490-496
4. Cortese MM, Wolff M, Almeido-Hill J, Reid R, Ketcham J, Santosham M. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. Arch Intern Med. 1992;152(11):2277-2282
5. Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. Clin Infect Dis. 1998;26(3):590-595 (Pubitemid 28155004)
6. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000;49(9):1-35
7. Gessner BD, Ussery XT, Parkinson AJ, Breiman RF. Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaska native children younger than two years of age. Pediatr Infect Dis J. 1995;14(2):123-128
8. Levine O, Farley M, Harrison L, et al. Rick factors for invasive pneumococcal disease in children: a population -based case-control study in North America. Pediatrics. 1999;103(3). Available at: www.pediatrics.org/cgi/ content/full/103/3/e28
9. Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24 -59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep. 2008;57(13):343-344
10. Whitney C, Farley M, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746 (Pubitemid 36514704)
11. Black S, Shinefield H, Baxter R, et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine. 2006;24(suppl 2):S2/79-S2/80
12. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3 pt 1):443-449
13. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495-1502
14. US Census Bureau. Population estimates. Available at: www.census.gov/popest/datasets.html. Accessed April 27, 2010
15. Schuchat A, Hilger T, Zell E, et al. Update from the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Emerg Infect Dis. 2001;7(1):92-99
16. SAS Institute Inc. SAS Version 9.1 [computer program]. Cary, NC: SAS Institute Inc; 2002-2003
17. Flannery B, Schrag S, Bennett N, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004;291(18):2197-2203
18. Talbot TR, Poehling KA, Hartert TV, et al. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr Infect Dis J. 2004;23(8):726-731
19. Moore MR, Gertz RE, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016-1027
20. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction: eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008;57(6):144-148
21. Immunization Action Coalition. Vaccination information for healthcare professionals: pneumococcal conjugate vaccine mandates for children in daycare. Available at: www.immunize.org/laws/pneuconj.asp. Accessed June 1, 2009
22. Smith PJ, Nuorti JP, Singleton JA, Zhao Z, Wolter KM. Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey. Pediatrics. 2007;120(5). Available at: www.pediatrics.org/cgi/content/full/120/5/e1165
23. Nuorti JP, Martin SW, Smith PJ, Moran JS, Schwartz B. Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts. Am J Prev Med. 2008;34(1):46-53
24. Centers for Disease Control and Prevention. Notice to readers: decreased availability of pneumococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep. 2001. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm5036a3.htm. Accessed April 27, 2010
25. Centers for Disease Control and Prevention. Notice to readers: limited supply of pneumococcal conjugate vaccine - suspension of recommendation for fourth dose. MMWR Morb Mortal Wkly Rep. 2004. Available at: www.cdc.gov/mmwr/ preview/mmwrhtml/mm5305a6.htm. Accessed April 27, 2010
26. Stokley S, Shaw KM, Barker L, Santoli JM, Shefer A. Impact of state vaccine financing policy on uptake of heptavalent pneumococcal conjugate vaccine. Am J Public Health. 2006;96(7):1308-1313
27. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341-1348
28. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121(3):562-569
29. O'Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 among infants with sickle cell disease. Pediatrics. 2000;106(5):965-972
30. Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr. 1998;133(2):275-278 (Pubitemid 28385210)
31. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428-1433
32. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007;25(13):2451-2457 (Pubitemid 46389429)
33. Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005;24(5):410-416
34. Nuorti J, Butler J, Farley M, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med. 2000;342(10):681-689 (Pubitemid 30131420)
35. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295(14):1668-1674